{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T06:34:36Z","timestamp":1793169276490,"version":"4.5.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"37","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,11]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Triple-negative breast cancer (TNBC) is defined as the absence of estrogen receptor and progesterone receptor expression, along with a lack of human epidermal growth factor receptor 2 overexpression or amplification. Patients with TNBC exhibit a poorer prognosis, characterized by a higher propensity for metastasis to the lungs, liver, and brain, and a lower overall survival rate than other breast cancer subtypes. Primary treatment modalities for TNBC include surgery, chemotherapy, and radiotherapy. Although stereotactic body radiotherapy (SBRT) has been reported for the treatment, there is a paucity of comprehensive research in this field.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>We report a case of successful treatment of a 38-year-old female patient with TNBC who experienced recurrence after surgery. The tumor occurred 1 year after surgery. The tumor showed rapid progression and growth.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Stage \u2163 TNBC with lung metastasis<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>After visiting multiple hospitals, the patient finally underwent SBRT combined with chemotherapy. During SBRT implementation, an ultrahigh-dose radiotherapy modality was adopted, which is a rarely reported approach in previous studies. Subsequently, a conventional fractionated radiotherapy regimen was administered. Concurrent with radiotherapy, the patient received 2 cycles of chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>The patient\u2019s tumor shrank rapidly, with minimal adverse reactions. Nine months later, the tumor remained well controlled.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>Treatment of TNBC remains challenging. Given the aggressive progression of the tumor, a new radiotherapy regimen was adopted. Given that such an approach has scarcely been documented in the published literature, this case may offer novel implications for clinical practitioners.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050561","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:08:23Z","timestamp":1789142903000},"page":"e50561","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Successful treatment of a large-sized triple-negative breast cancer"],"prefix":"10.1097","volume":"105","author":[{"given":"Dong","family":"Zeng","sequence":"first","affiliation":[{"name":"Institute of Cancer, Sichuan Friendship Hospital, Chengdu, Sichuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolan","family":"Liu","sequence":"additional","affiliation":[{"name":"Institute of Cancer, Sichuan Friendship Hospital, Chengdu, Sichuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenya","family":"Fu","sequence":"additional","affiliation":[{"name":"Institute of Cancer, Sichuan Friendship Hospital, Chengdu, Sichuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Liu","sequence":"additional","affiliation":[{"name":"Institute of Cancer, Sichuan Friendship Hospital, Chengdu, Sichuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuezhu","family":"Zhao","sequence":"additional","affiliation":[{"name":"Institute of Cancer, Sichuan Friendship Hospital, Chengdu, Sichuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luo","family":"Zhong","sequence":"additional","affiliation":[{"name":"Institute of Cancer, Sichuan Friendship Hospital, Chengdu, Sichuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4382-9641","authenticated-orcid":false,"given":"Xiaohui","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Cancer, Sichuan Friendship Hospital, Chengdu, Sichuan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261028","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R2-20261028","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress.","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res"},{"key":"R3-20261028","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.22381","article-title":"Prognostic markers in triple-negative breast cancer.","volume":"109","author":"Rakha","year":"2007","journal-title":"Cancer"},{"key":"R4-20261028","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nrc3896","article-title":"Triple-negative breast cancer in African-American women: disparities versus biology.","volume":"15","author":"Dietze","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"R5-20261028","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.2217\/fon-2023-0301","article-title":"Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer.","volume":"20","author":"Haiderali","year":"2024","journal-title":"Future Oncol"},{"key":"R6-20261028","doi-asserted-by":"crossref","first-page":"13518","DOI":"10.3390\/ijms252413518","article-title":"Latest therapeutical approaches for triple-negative breast cancer: from preclinical to clinical research.","volume":"25","author":"Pont","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R7-20261028","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1002\/1097-0142(19811015)48:8<1863::AID-CNCR2820480825>3.0.CO;2-U","article-title":"Findings from NSABP Protocol No. B-04: comparison of radical mastectomy with alternative treatments. II. The clinical and biologic significance of medial-central breast cancers.","volume":"48","author":"Fisher","year":"1981","journal-title":"Cancer"},{"key":"R8-20261028","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1200\/JCO.20.01024","article-title":"Hypofractionated versus conventional fractionated radiotherapy after breast-conserving surgery in the modern treatment era: a multicenter, randomized controlled trial from China.","volume":"38","author":"Wang","year":"2020","journal-title":"J Clin Oncol"},{"key":"R9-20261028","doi-asserted-by":"crossref","first-page":"102939","DOI":"10.1016\/j.ctrv.2025.102939","article-title":"Enhancing radiotherapy techniques for triple-negative breast cancer treatment.","volume":"136","author":"Sarlak","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"R10-20261028","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1515\/med-2020-0138","article-title":"A review of current progress in triple-negative breast cancer therapy.","volume":"15","author":"Shen","year":"2020","journal-title":"Open Med (Wars)"},{"key":"R11-20261028","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1634\/theoncologist.2014-0002","article-title":"Measures of outcome in metastatic breast cancer: insights from a real-worldscenario.","volume":"19","author":"Bonotto","year":"2014","journal-title":"Oncologist"},{"key":"R12-20261028","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1634\/theoncologist.2017-0095","article-title":"Targeting the molecular subtypes of triple negative breast cancer: understanding the diversity to progress the field.","volume":"22","author":"Yam","year":"2017","journal-title":"Oncologist"},{"key":"R13-20261028","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.breast.2022.02.006","article-title":"Is breast conservation superior to mastectomy in early stage triple negative breast cancer?","volume":"62","author":"Saifi","year":"2022","journal-title":"Breast"},{"key":"R14-20261028","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.3747\/co.25.3954","article-title":"Advances in the systemic treatment of triple-negative breast cancer.","volume":"25","author":"Lebert","year":"2018","journal-title":"Curr Oncol"},{"key":"R15-20261028","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"key":"R16-20261028","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1158\/1078-0432.CCR-13-0799","article-title":"Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes.","volume":"19","author":"Masuda","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R17-20261028","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.3390\/cancers17244023","article-title":"Real-world neoadjuvant systemic therapy utilization and treatment patterns in patients with early-stage or locally advanced triple-negative breast cancer in Greece-the TRINITY STUDY.","volume":"17","author":"Papazisis","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"Suppl 5","key":"R18-20261028","doi-asserted-by":"crossref","first-page":"v8","DOI":"10.1093\/annonc\/mdv298","article-title":"Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.","volume":"26","author":"Senkus","year":"2015","journal-title":"Ann Oncol"},{"key":"R19-20261028","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1093\/annonc\/mdx036","article-title":"3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3).","volume":"28","author":"Cardoso","year":"2017","journal-title":"Ann Oncol"},{"key":"R20-20261028","doi-asserted-by":"crossref","first-page":"682","DOI":"10.14423\/SMJ.0000000000001882","article-title":"Molecular subtypes and radiotherapy as determinants of survival in invasive breast cancer: insights from a single-center study.","volume":"118","author":"Liu","year":"2025","journal-title":"South Med J"},{"key":"R21-20261028","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1055\/s-0045-1809176","article-title":"Preoperative radiotherapy (Preop-RT) improves pathological complete response rates in partial responders (PR) to primary systemic chemotherapy (PST) in locally advanced breast cancers (LABC).","volume":"14","author":"Agrawal","year":"2025","journal-title":"South Asian J Cancer"},{"key":"R22-20261028","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1200\/JCO.2010.33.4714","article-title":"Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy.","volume":"29","author":"Abdulkarim","year":"2011","journal-title":"J Clin Oncol"},{"key":"R23-20261028","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.radonc.2011.07.007","article-title":"Adjuvant chemotherapy and radiotherapy in triple-negative breast carcinoma: a prospective randomized controlled multi-center trial.","volume":"100","author":"Wang","year":"2011","journal-title":"Radiother Oncol"},{"key":"R24-20261028","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.critrevonc.2018.09.004","article-title":"Radiotherapy in triple-negative breast cancer: current situation and upcoming strategies.","volume":"131","author":"He","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"R25-20261028","doi-asserted-by":"crossref","first-page":"104546","DOI":"10.1016\/j.breast.2025.104546","article-title":"Impact of stereotactic body radiation therapy on systemic therapeutic line change in oligometastatic breast cancer.","volume":"83","author":"Leblanc","year":"2025","journal-title":"Breast"},{"key":"R26-20261028","doi-asserted-by":"crossref","first-page":"6976","DOI":"10.3390\/curroncol30070505","article-title":"The effectiveness and safety of stereotactic body radiation therapy (SBRT) in the treatment of oligoprogressive breast cancer: a systematic review.","volume":"30","author":"Yan","year":"2023","journal-title":"Curr Oncol"},{"key":"R27-20261028","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1080\/21645515.2020.1840254","article-title":"Effect of radiotherapy on T cell and PD-1\/ PD-L1 blocking therapy in tumor microenvironment.","volume":"17","author":"Chen","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"R28-20261028","doi-asserted-by":"crossref","first-page":"27","DOI":"10.29063\/ajrh2025\/v29i7.3","article-title":"Effect and mechanism of local radiotherapy combined with immune checkpoint inhibitor in the treatment of metastatic triple negative breast cancer.","volume":"29","author":"Lu","year":"2025","journal-title":"Afr J Reprod Health"},{"key":"R29-20261028","doi-asserted-by":"crossref","first-page":"e025556","DOI":"10.1136\/bmjopen-2018-025556","article-title":"RadComp (Radiotherapy Comparative Effectiveness Consortium). Pragmatic randomised clinical trial of proton versus photon therapy for patients with non-metastatic breast cancer: the Radiotherapy Comparative Effectiveness (RadComp) consortium trial protocol.","volume":"9","author":"Bekelman","year":"2019","journal-title":"BMJ Open"},{"key":"R30-20261028","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1101\/gad.334516.119","article-title":"PARP and PARG inhibitors in cancer treatment.","volume":"34","author":"Slade","year":"2020","journal-title":"Genes Dev"},{"key":"R31-20261028","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3390\/jcm9040940","article-title":"Response of breast cancer cells to PARP inhibitors is independent of BRCA status.","volume":"9","author":"Keung","year":"2020","journal-title":"J Clin Med"},{"key":"R32-20261028","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.bulcan.2019.12.012","article-title":"Androgen receptor-positive triple negative breast cancer: from biology to therapy.","volume":"107","author":"Grellety","year":"2020","journal-title":"Bull Cancer"},{"key":"R33-20261028","doi-asserted-by":"crossref","first-page":"e70615","DOI":"10.1002\/cam4.70615","article-title":"Prognostic value of Trop-2 expression in nonmetastatic triple-negative breast cancer and correlation with emerging biomarkers.","volume":"14","author":"Jacot","year":"2025","journal-title":"Cancer Med"},{"key":"R34-20261028","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/s41591-025-03630-w","article-title":"Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial.","volume":"31","author":"Yin","year":"2025","journal-title":"Nat Med"},{"key":"R35-20261028","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12916-019-1326-5","article-title":"Recent advances in triple negative breast cancer: the immunotherapy era.","volume":"17","author":"Marra","year":"2019","journal-title":"BMC Med"},{"key":"R36-20261028","doi-asserted-by":"crossref","first-page":"1676768","DOI":"10.3389\/fimmu.2025.1676768","article-title":"A tumor immune microenvironment gene expression signature for predicting prognosis, immunotherapy efficacy, and drug candidates in triple-negative breast cancer.","volume":"16","author":"Bai","year":"2025","journal-title":"Front Immunol"},{"key":"R37-20261028","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer.","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"R38-20261028","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"key":"R39-20261028","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/s41467-024-45160-y","article-title":"The anti-PD-L1\/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: a multicenter phase II trial.","volume":"15","author":"Li","year":"2024","journal-title":"Nat Commun"},{"key":"R40-20261028","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/13543784.2022.2054326","article-title":"CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress.","volume":"31","author":"Corti","year":"2022","journal-title":"Expert Opin Investig Drugs"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050561","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T06:01:10Z","timestamp":1793167270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050561"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":40,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050561","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"2026-01-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}